Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy
1Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, PR China.
Journal of Clinical Psychopharmacology
|February 21, 2013
Summary
Genetic variations in the histamine H4 receptor (HRH4) gene influence how well patients respond to risperidone treatment for schizophrenia. A specific HRH4 gene variant, rs4483927, was identified as a predictor of poor therapeutic outcomes.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Psychiatry
Background:
- Histamine H4 receptor (HRH4) plays a role in antipsychotic treatment response.
- Understanding genetic factors influencing drug efficacy is crucial for personalized medicine in schizophrenia treatment.
Purpose of the Study:
- To investigate the association between human HRH4 gene polymorphisms and risperidone efficacy in Chinese Han patients with schizophrenia.
- To identify potential genetic markers for predicting individual responses to risperidone therapy.
Main Methods:
- Genotyping of 5 tag-single nucleotide polymorphisms (SNPs) in the HRH4 gene in 113 schizophrenia patients.
- Analysis of the association between HRH4 genotypes and the reduction in Positive and Negative Syndrome Scale (PANSS) scores after 8 weeks of risperidone monotherapy.
- Statistical analyses included chi-squared, analysis of variance, haplotype, and receiver operating characteristic (ROC) analyses.
Main Results:
- The common variant rs4483927 in the HRH4 gene was significantly associated with risperidone efficacy.
- The TT genotype of rs4483927 was found to predict a poor therapeutic response across all PANSS subscales (positive, negative, general) and the total score (P = 0.017, 0.019, 0.021, and 0.002, respectively).
- Haplotype and ROC analyses further supported the association.
Conclusions:
- This study provides the first evidence that an HRH4 gene polymorphism can serve as a molecular marker for predicting risperidone efficacy in schizophrenia treatment.
- The findings suggest a novel pharmacogenetic link between the HRH4 gene and the effectiveness of risperidone therapy for schizophrenia.
- These results may contribute to the development of individualized treatment strategies for schizophrenia based on patient genetics.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...